이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bloomage BioTechnology 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yan Zhao

최고 경영자

CN¥2.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	0.02%
경영진 평균 재임 기간	4.6yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

업데이트 없음

Recent updates

Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly

Jun 02

Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)

May 06

Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult

May 01

CEO

Yan Zhao (58 yo)

no data

테뉴어

CN¥2,024,900

보상

Ms. Yan Zhao serves as the Chairwoman at Pando Group Limited. She is also the majority shareholder in and serves as Chairman and Executive Director of Bloomage BioTechnology Corporation Limited and serves...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yan Zhao	Chairman & GM	no data	CN¥2.02m	0.024% CN¥ 6.6m
Jiajun Guo	Deputy GM & Director	no data	CN¥925.30k	0.012% CN¥ 3.1m
Xueping Guo	Deputy GM of Core Technician & Director	no data	CN¥946.70k	0.017% CN¥ 4.6m
Yizheng Li	Deputy GM	no data	CN¥1.70m	데이터 없음
Aihua Liu	Deputy General Manager	no data	CN¥1.82m	0.015% CN¥ 4.0m
Guixin Xu	Deputy General Manager	5.3yrs	CN¥734.90k	0.0092% CN¥ 2.5m
Gao Yi	Deputy General Manager	3.4yrs	CN¥1.00m	0.0026% CN¥ 712.0k
Luan Yizheng	Deputy General Manager	4.6yrs	CN¥1.01m	0.012% CN¥ 3.1m

4.6yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: 688363 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yan Zhao	Chairman & GM	no data	CN¥2.02m	0.024% CN¥ 6.6m
Jiajun Guo	Deputy GM & Director	no data	CN¥925.30k	0.012% CN¥ 3.1m
Xueping Guo	Deputy GM of Core Technician & Director	no data	CN¥946.70k	0.017% CN¥ 4.6m
Yizheng Li	Deputy GM	no data	CN¥1.70m	데이터 없음
Yingqian Wang	Independent Director	5.3yrs	CN¥150.00k	데이터 없음
Fuguo Cao	Independent Director	5.3yrs	CN¥150.00k	데이터 없음
Changmei Zhao	Supervisor	4.1yrs	데이터 없음	데이터 없음
Dongni Li	Employee Representative Supervisor	4.1yrs	데이터 없음	데이터 없음
Jing Yu	Chairman of the Supervisory Board	no data	데이터 없음	데이터 없음
Songyan Zou	Director	2.3yrs	CN¥626.90k	0.0019% CN¥ 508.9k
Yuan Fan	Director	2.3yrs	CN¥862.90k	0.0038% CN¥ 1.0m
Guanting Chen	Independent Director	2.3yrs	CN¥150.00k	데이터 없음

4.1yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: 688363 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

Bloomage BioTechnology 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Recent updates

Bloomage BioTechnology Corporation Limited to Report First Half, 2024 Results on Aug 24, 2024

Bloomage BioTechnology (SHSE:688363) Seems To Use Debt Quite Sensibly

Weak Statutory Earnings May Not Tell The Whole Story For Bloomage BioTechnology (SHSE:688363)

Price target decreased by 9.9% to CN¥75.39

Getting In Cheap On Bloomage BioTechnology Corporation Limited (SHSE:688363) Might Be Difficult

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 9.9% to CN¥83.72

Bloomage BioTechnology Corporation Limited to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 20% overvalued

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 8.6% to CN¥99.40

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 18%

Consensus revenue estimates fall by 12%

Second quarter 2023 earnings: EPS misses analyst expectations

Bloomage BioTechnology Corporation Limited (SHSE:688363) announces an Equity Buyback for CNY 300 million worth of its shares.

Bloomage BioTechnology Corporation Limited to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 7.9% to CN¥120

Price target decreased by 8.2% to CN¥126

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥150

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to CN¥168

Second quarter 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥153

Price target decreased to CN¥181

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥196

Price target decreased to CN¥239

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.35 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.33 in 2Q 2020)

Price target increased to CN¥245

First quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.23 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.35 (vs CN¥1.34 in FY 2019)

New 90-day low: CN¥134

New 90-day high: CN¥208

New 90-day high: CN¥192

Price target raised to CN¥175

New 90-day high: CN¥150

Bloomage BioTechnology Corporation Limited to Report Q3, 2020 Results on Oct 30, 2020

Bloomage BioTechnology Corporation Limited (SHSE:688363) completed the acquisition of Dongying Fusite Biological Engineering Co., Ltd. from Eastar Holdings Group CO.,LTD and Zhang Zhenwu.

New 90-day low - CN¥119

First half earnings released

Bloomage BioTechnology Corporation Limited to Report First Half, 2020 Results on Aug 26, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령